DCVAC/OvCa

March 27, 2019

Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows

News

Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 ... Read more

November 29, 2017

SOTIO Enrolls First Patient in Another Phase 2 Trial of Its Ovarian Cancer Immunotherapy

News

SOTIO has enrolled its first ovarian cancer patient in a Phase 2 clinical trial evaluating its immunotherapy DCVAC/OvCa. The SOV06 trial will look at the therapy’s effectiveness as an add-on to ... Read more